227. オスラー病
[臨床試験数:49,薬物数:69(DrugBank:21),標的遺伝子数:23,標的パスウェイ数:132]
Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2018-004179-11-DE (EUCTR) | 12/08/2020 | 12/03/2020 | The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia(a.k.a. Rendu-Osler-Weber disease) patients who suffer fromgastrointestinal bleeding. | Effectiveness of Somatostatin Analogues in Patients with hereditaryhemorrhagic telangiectasia and symptomatic gastrointestinal bleeding,the SAIPAN-trial: a multicenter, randomized, open-label, parallel-group,superiority trial. - SAIPAN-trial | Hereditary hemorrhagic telangiectasia (HHT), also known as Osler–Weber–Rendu disease (in specific patients with gastrointestinalbleedings);Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Other descriptive name: OCTREOTIDE ACETATE | Radboudumc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 38 | Phase 3 | France;Netherlands;Germany;United Kingdom;Italy | ||
2 | EUCTR2018-004179-11-NL (EUCTR) | 03/06/2019 | 14/05/2019 | The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia (a.k.a. Rendu-Osler-Weber disease) patients who suffer from gastrointestinal bleeding. | Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding, the SAIPAN-trial: a multicenter, randomized, open-label, parallelgroup, superiority trial. - SAIPAN-trial | Hereditary hemorrhagic telangiectasia (HHT);Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Radboudumc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 38 | Phase 3 | Netherlands | |||
3 | NCT02874326 (ClinicalTrials.gov) | October 2016 | 17/8/2016 | Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber | An Uncontrolled, Pilot-study Assessing the Efficacy of Octreotide Long-acting Release to Decrease Transfusion Requirements and Endoscopy Frequency in Patients With Rendu-Osler-Weber and Gastrointestinal Bleeding | Hereditary Hemorrhagic Telangiectasia;Gastrointestinal Hemorrhage;Anemia | Drug: Octreotide LAR | Radboud University | St. Antonius Hospital | Unknown status | 18 Years | N/A | All | 15 | Phase 2 | Netherlands |
4 | EUCTR2016-001340-19-NL (EUCTR) | 21/07/2016 | 11/07/2016 | The effectiveness of the drug octreotide LAR to anemia in patients with gastrointestinal bleeding due to Rendu-Osler-Weber disease. | An uncontrolled, pilot-study assessing the efficacy of octreotide LAR to decrease transfusion requirements and endoscopy frequency in patients with Rendu-Osler-Weber and gastrointestinal bleeding - ROW | Patients with Rendu-Osler-Weber disease (which is also called: Hereditary hemorrhagic telangiectasia);Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: Sandostatin LAR 20 mg Product Name: Sandostatin LAR Product Code: RVG 18236 | Radboud University Medical Center | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | Netherlands | |||
5 | NCT00004327 (ClinicalTrials.gov) | January 1995 | 18/10/1999 | Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia | Hereditary Hemorrhagic Telangiectasia;Ectasia | Drug: octreotide | National Center for Research Resources (NCRR) | Yale University | Completed | N/A | N/A | Both | 8 | Phase 2 | NULL |